Target-specific biomarkers have been used as commonplace to assess drug response, including assessment of levels of p53, p21, MDM2, Ki-67, and blood macrophage inhibitory factor (MIC-1) for MDM2 inhibitors in liposarcoma [76] and c-Myc mRNA/protein levels and assessment of expression of bromodomain 4-dependent genes following use of BET inhibitors in xenograft models of Burkitt's lymphoma [77]. The gene discussed is MDM2; the disease is Burkitt lymphoma.